drugset / Trial / NCT03150134

Early Tapering of Immunosuppressive Agents to Immunomodulation to Improve Survival of AML Patients

NCT03150134

Non-randomizedParallel-groupOpen-labelTreatment

Summary

Early reduction of immunosuppressive agents after HLA matched donor transplantation can improve the survival of advanced stage acute myeloid leukemia. single-center, open clinical study

Timeline

Start
2010-01-01
Primary completion
2020-01-01
Completion
2021-01-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Cyclosporine Peptide